Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.

This year, for the first time, the American Society of Clinical Oncology (ASCO) is publishing Clinical Cancer Advances 2005: Major Research Advances in Cancer Treatment, Prevention, and Screening, an annual review of the most significant clinical research presented or published over the past year across all cancer types. ASCO embarked on this project to provide the public, patients, policymakers, and physicians with an accessible summary of the year's most important research advances. While not intended to serve as a comprehensive review, this report provides a year-end snapshot of research that will have the greatest impact on patient care. As you will read, there is much good news from the front lines of cancer research. These pages report on new chemotherapy regimens that sharply reduce the risk of recurrence for very common cancers; the "coming of age" of targeted cancer therapies; promising studies of drugs to prevent cancer; and improvements in quality of life for people living with the disease, among many other advances. Survival rates for cancer are on the rise, increasing from 50% to 64% over the last 30 years. Cancer still exacts an enormous toll, however. Nearly 1.4 million Americans will be diagnosed this year, and some 570,000 will die of the disease. Clearly, more research is needed to find effective therapies for the most stubborn cancer types and stages. We need to know more about the long-term effects of newer, more targeted cancer therapies, some of which need to be taken over long periods of time. And we need to devote far greater attention to tracking and improving the care of the nearly 10 million cancer survivors in the United States today. Despite these and other challenges, the message of this report is one of hope. Through the dedicated, persistent pursuit of clinical research and participation in clinical trials by people with cancer, we steadily uncover new and better ways of treating, diagnosing, and preventing a disease that touches the lives of so many. I want to thank the Editorial Board members, the Specialty Editors, and the ASCO Cancer Communications Committee for their dedicated work to develop this report, and I hope you find it useful.

[1]  J. Meyerhardt,et al.  Influence of regular aspirin use on survival for patients with stage III colon cancer: Findings from Intergroup trial CALGB 89803 , 2005 .

[2]  M. Hudson,et al.  Prevalence and severity of chronic diseases in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study , 2005 .

[3]  Mark Levine,et al.  Radiation therapy and tamoxifen: concurrent or sequential? That is the question. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  R. Rosell,et al.  ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts): Final results after 70-month median follow-up. On behalf of the Adjuvant Navelbine International Trialist Association , 2005 .

[5]  M. Pfreundschuh,et al.  Treatment results of CHOP-21, CHOEP-21, MACOP-B and PMitCEBO with and without rituximab in young good-prognosis patients with aggressive lymphomas: Rituximab as an “equalizer” in the MInT (MABTHERA International Trial Group) study , 2005 .

[6]  P. Murawa,et al.  Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Motzer,et al.  Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC) , 2005 .

[8]  J. Meyerhardt,et al.  Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. , 2005, JAMA.

[9]  K. Ang,et al.  Improved preservation of larynx with the addition of cetuximab to radiation for cancers of the larynx and hypopharynx , 2005 .

[10]  Cosette M Wheeler,et al.  Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. , 2005, The Lancet. Oncology.

[11]  Vikas Khurana,et al.  Statins and prostate cancer risk: A large case control study in veterans , 2005 .

[12]  R. Bukowski,et al.  Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC) , 2005 .

[13]  Richard L Wahl,et al.  131I-tositumomab therapy as initial treatment for follicular lymphoma. , 2005, The New England journal of medicine.

[14]  Daron G Ferris,et al.  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial , 2004, The Lancet.

[15]  R. Gray,et al.  Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599 , 2005 .

[16]  R. Schilsky,et al.  Randomized Clinical Trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB Non-Small Cell Lung Cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Hainsworth,et al.  Bevacizumab and erlotinib in the treatment of patients with metastatic renal carcinoma (RCC): Update of a phase II multicenter trial , 2005 .

[18]  J. Forbes,et al.  BIG 1-98: Randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer , 2005 .

[19]  A. Zelenetz,et al.  Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Ratain,et al.  Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC) , 2005 .

[21]  Patricia A. Ganz,et al.  From cancer patient to cancer survivor : lost in transition , 2006 .

[22]  D. Ransohoff,et al.  Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. , 2004, The New England journal of medicine.

[23]  J. Sudbø,et al.  Non-steroidal anti-inflammatory drugs and the risk of oral cancer in current and former smokers - [REMOVED] , 2005 .

[24]  A. Saykin,et al.  Quality of life of long-term survivors of breast cancer and lymphoma treated with standard-dose chemotherapy or local therapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Robert Livingston,et al.  Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. , 2005, The New England journal of medicine.

[26]  T. Fears,et al.  Pediatric melanoma: risk factor and survival analysis of the surveillance, epidemiology and end results database. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Michael L. Wang,et al.  Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[29]  J. Roy,et al.  A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients. , 2005, Journal of the National Cancer Institute.

[30]  Vikas Khurana,et al.  Statins to reduce breast cancer risk: A case control study in U.S. female veterans , 2005 .

[31]  L. Willett Vitamin E did not prevent cardiovascular disease and cancer in healthy women , 2006, Evidence-based medicine.

[32]  S. Yusuf,et al.  Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. , 2005, JAMA.

[33]  J. Manson,et al.  Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer: The Women’s Health Study: A Randomized Controlled Trial , 2005, JAMA.

[34]  Graham A. Colditz,et al.  Physical activity and survival after breast cancer diagnosis , 2005 .

[35]  Ronit Almog,et al.  Statins and the risk of colorectal cancer. , 2005, The New England journal of medicine.

[36]  Vikas Khurana,et al.  Statins reduce the incidence of lung cancer: A study of half a million U.S. veterans , 2005 .

[37]  C. D'Orsi,et al.  Diagnostic Performance of Digital Versus Film Mammography for Breast-Cancer Screening , 2005, The New England journal of medicine.

[38]  T. Pietsch,et al.  Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. , 2005, The New England journal of medicine.

[39]  B. Barlogie,et al.  Results of total therapy 2 (TT 2), a phase III randomized trial, to determine the role of thalidomide (THAL) in the upfront management of multiple myeloma (MM) , 2005 .

[40]  J. Meyerhardt,et al.  The impact of physical activity on patients with stage III colon cancer: Findings from Intergroup trial CALGB 89803 , 2005 .

[41]  R. Motzer,et al.  AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC) , 2005 .

[42]  G. Demetri,et al.  Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST , 2005 .

[43]  N. Coburn,et al.  Significant regional variation in treatment and survival of gastric cancer , 2005 .

[44]  N. Wolmark,et al.  A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Survival results of NSABP Protocol C-07 , 2005 .

[45]  S. Lippman,et al.  Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  C. Vachon,et al.  Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. , 2005, JAMA.

[47]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[48]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[49]  C. Gluud,et al.  Antioxidant supplements for prevention of gastrointestinal cancers: a systematic review and meta-analysis , 2004, The Lancet.

[50]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[51]  J. Gardiner,et al.  Cancer, Medicaid enrollment, and survival disparities , 2005, Cancer.

[52]  D. Cunningham,et al.  Perioperative chemotherapy in operable gastric and lower oesophageal cancer: Final results of a randomised, controlled trial (the MAGIC trial, ISRCTN 93793971) , 2005 .

[53]  M Baum,et al.  Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer , 2005, The Lancet.

[54]  A. Giuliano,et al.  Dietary fat reduction in postmenopausal women with primary breast cancer: Phase III Women's Intervention Nutrition Study (WINS) , 2005 .

[55]  E. Paulson,et al.  Analysis of air contrast barium enema, computed tomographic colonography, and colonoscopy: prospective comparison , 2005, The Lancet.

[56]  E. Guadagnoli,et al.  Do increases in the market share of managed care influence quality of cancer care in the fee-for-service sector? , 2005, Journal of the National Cancer Institute.

[57]  Stephen D. Persell,et al.  Low-Dose Aspirin Does Not Reduce Cancer Incidence in Women Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005;294:47-55. , 2005 .

[58]  P. Greenberg,et al.  Hematologic and cytogenetic (CTG) response to lenalidomide (CC-5013) in patients with transfusion-dependent (TD) myelodysplastic syndrome (MDS) and chromosome 5q31.1 deletion: Results of the multicenter MDS-003 Study , 2005 .